Literature DB >> 26516101

Serum level of venlafaxine is associated with better memory in psychotic disorders.

Nils Eiel Steen1, Monica Aas2, Carmen Simonsen2, Ingrid Dieset2, Martin Tesli2, Mari Nerhus2, Erlend Gardsjord2, Ragni Mørch2, Ingrid Agartz3, Ingrid Melle2, Anja Vaskinn4, Olav Spigset5, Ole A Andreassen2.   

Abstract

Cognitive impairment is a core feature of psychosis spectrum disorders. Antipsychotics have at best small positive effects on cognitive performance. There is a lack of knowledge regarding the effects of antidepressants on cognitive functioning in these disorders. In the present study cognitive performance was investigated in relation to serum levels of antidepressants in persons with bipolar disorder and schizophrenia. Serum concentrations of escitalopram, citalopram and venlafaxine plus O-desmethylvenlafaxine were measured in a total of 187 participants with bipolar disorder (N=74) or schizophrenia spectrum disorders (N=113), and analyzed in relation to neuropsychological tests performance of verbal learning, verbal memory, attention, working memory, executive functioning and processing speed. Analyses were performed using linear regression adjusting for a range of confounders. There was a significant positive association between the serum level of venlafaxine plus O-desmethylvenlafaxine and verbal memory (immediate recall: Logical Memory Test immediate recall [p=0.015], and long term delayed recall: Logical Memory Test delayed recall [p=0.011]). No significant associations were seen between citalopram or escitalopram and verbal memory. There were no significant associations between the tested antidepressants and verbal learning, attention, working memory, executive functioning, or processing speed. Venlafaxine seem to be associated with better verbal memory in bipolar disorder and schizophrenia. This suggests a possible beneficial role of certain antidepressants on cognitive dysfunction, which may have clinical implications and provide insight into underlying pathophysiology. However, the current findings should be replicated in independent samples.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antidepressants; Bipolar disorder; Cognition; Neuropsychological test; Psychosis; Schizophrenia

Mesh:

Substances:

Year:  2015        PMID: 26516101     DOI: 10.1016/j.schres.2015.10.021

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  3 in total

Review 1.  Cognitive Impairment in Patients with Bipolar Disorder: Impact of Pharmacological Treatment.

Authors:  Ni Xu; Benjamin Huggon; Kate E A Saunders
Journal:  CNS Drugs       Date:  2020-01       Impact factor: 5.749

2.  Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine.

Authors:  Maxim Kuzin; Georgios Schoretsanitis; Ekkehard Haen; Benedikt Stegmann; Christoph Hiemke; Gerhard Gründer; Michael Paulzen
Journal:  Clin Pharmacokinet       Date:  2018-06       Impact factor: 6.447

3.  Serum concentrations of mood stabilizers are associated with memory, but not other cognitive domains in psychosis spectrum disorders; explorative analyses in a naturalistic setting.

Authors:  Nils Eiel Steen; Monica Aas; Carmen Simonsen; Ingrid Dieset; Martin Tesli; Mari Nerhus; Erlend Gardsjord; Ragni Mørch; Ingrid Agartz; Ingrid Melle; Anja Vaskinn; Olav Spigset; Ole A Andreassen
Journal:  Int J Bipolar Disord       Date:  2016-12-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.